scRNA-seq also helped to reveal biomarkers that could serve as indicators of successful T1DM treatment with teplizumab (IL7R, CD127), and potential targets for monoclonal antibody treatment (TLR4, TRAJ23, IL23). This evidence concerns the gene TRAJ23 and type 1 diabetes mellitus.